Dr. Reddy's signs exclusive distribution deal for Takeda's dengue vaccine Qdenga in India

Strategic Transactions View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1175.00

prior close

₹1182.60

announcement price

After-mkt

timing

Nifty 100market+0.5%+0.4% vs market

Pharmaceuticals peers, median of 172sector+0.6%+0.3% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.8

15m

+1.1

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+0.5+0.4+0.6+0.3

Next day

+2.3+0.7+1.5+1.1+1.2

+2.7+0.4+2.3+1.1+1.7

+3.4+1.0+2.4+2.0+1.3

+2.2-0.7+2.8+0.8+1.4

+2.2-0.3+2.5+0.5+1.7

+6.5-2.4+8.9+0.1+6.4

15d

+4.6-3.9+8.5-4.3+9.0

+5.7-2.0+7.7-6.1+11.8

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's has entered an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga, India's first CDSCO-approved dengue vaccine, in India's private market. Approved in July 2026 for ages 4 to 60, the vaccine is expected to launch in H1 2027. No upfront or milestone payments; commercial terms are confidential. Dengue cases in India have grown 11-fold over the past two decades.

Likely market impact

Strengthens Dr. Reddy's vaccine portfolio, the second-largest in India, and adds a high-demand product to support revenue diversification in the long term.